REPUBLIC OF LEBANON MINISTRY OF PUBLIC HEALTH Lebanon Clinical Trials Registry

Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2)

23/08/2025 08:09:28

Primary registry identifying number	Protocol number
BCTR2019050229	CLEE011A2301
MOH registration number	
ص/9695	
Study registered at the country of origin	Study registered at the country of origin: Specify
Yes	
Гуре of registration	Type of registration: Justify
Retrospective	LCTR was recently initiated, original file was previously submitted by Paper
Date of registration in national regulatory agency 05/11/2014	
Primary sponsor	Primary sponsor: Country of origin
Novartis Pharma Services Inc.	Novartis Pharmaceuticals
Date of registration in primary registry	Date of registration in national regulatory agency
29/07/2021	05/11/2014
Public title	Acronym
Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2)	
Scientific title	Acronym
A Randomized Double-blind, Placebo-controlled Study of LEE011 in Combination With Letrozole for the Treatment of Postmenopausal Nomen With Hormone Receptor Positive, HER2 Negative, Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease	
Brief summary of the study: English	
This is a multi-center, randomized, double-blinded, placebo controlled trial., The primary purpose of this study was to assess he efficacy of LEE011, as measured by progression free survival (PFS), in postmenopausal women with HR positive, HER2 negative advanced breast cancer who received no prior treatment for advanced disease.	
Brief summary of the study: Arabic	
زول LEE011 ددراسة عشوائية مزدوجة التعمية ومضبّطة بدواء و هميّ حول سلامة استخدام الدوا: في2النساء بعد انقطاع الطمث المصابات بسرطان ثدي متقمّ إيجابيّ مستقبلات الهرمون وسلبيّ الهير مراحله المتقدّما	
Health conditions/problem studied: Specify	
Advanced Breast Cancer	
nterventions: Specify	
Drug: LEE011 Ribociclib was administered orally at a dose of 600 mg once daily (three	200 mg cansules)

 \sim

REPUBLIC OF LEBANON Lebanon Clinical Trials Registry

Letrozole 2.5 mg tablets taken orally.

•Drug: LEE011 Placebo

Matching ribociclib placebo was the control drug and was administered orally once daily.

Key inclusion and exclusion criteria: Inclusion criteria

1.Women with advanced (locoregionally recurrent or metastatic) breast cancer not amenable to curative therapy.

2.Patient is postmenopausal. Postmenopausal status is defined either by:

Prior bilateral oophorectomy
 Age ≥60

^AGe <60 and amenorrhea for 12 or more months (in the absence of chemotherapy, tamoxifen, toremifen, or ovarian suppression) and FSH and estradiol in the postmenopausal range per local normal range Note: For women with therapy-induced amenorrhea, serial measurements of FSH and/or estradiol are needed to ensure postmenopausal status. Ovarian radiation or treatment with a luteinizing hormone-releasing hormone agonist (LH-RHa) (goserelin acetate or leuprolide acetate) is not permitted for induction of ovarian suppression in this trial.

3.No prior systemic anti-cancer therapy for advanced disease.

4.Patient has a histologically and/or cytologically confirmed diagnosis of estrogen-receptor positive and/or progesterone receptor positive breast cancer by local laboratory.

5.Patient has HER2-negative breast cancer defined as a negative in situ hybridization test or an IHC status of 0, 1+ or 2+. If IHC is 2+, a negative in situ hybridization (FISH, CISH, or SISH) test is required by local laboratory testing.

6.Patient must have either:

• Measurable disease, i.e., at least one measurable lesion as per RECIST 1.1 criteria (Tumor lesions previously irradiated or subjected to other locoregional therapy will only be considered measurable if disease progression at the treated site after completion of therapy is clearly documented).

OR

• If no measurable disease is present, then at least one predominantly lytic bone lesion must be present (Patients with no measurable disease and only one predominantly lytic bone lesion that has been previously irradiated are eligible if there is documented evidence of disease progression of the bone lesion after irradiation).

7.Patient has an Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

Key inclusion and exclusion criteria: Gender	Key inclusion and exclusion criteria: Specify gender
Female	
Key inclusion and exclusion criteria: Age minimum	Key inclusion and exclusion criteria: Age maximum
18	99

Key inclusion and exclusion criteria: Exclusion criteria

1.Patient who received any CDK4/6 inhibitor.

2.Patient who received any prior systemic anti-cancer therapy (including hormonal therapy and chemotherapy) for advanced breast cancer

Note:

Patients who received (neo) adjuvant therapy for breast cancer are eligible. If the prior neo (adjuvant) therapy included letrozole or anastrozole the disease free interval must be greater than 12 months from the completion of treatment until randomization.
 Patients who received ≤ 14 days of letrozole or anastrozole for advanced disease prior to randomization are eligible.

•Patients who received S 14 days of letrozole of anastrozole for advanced disease prior to randomization are eligible. •Any prior (neo) adjuvant anti-cancer therapy must be stopped at least 5 half-lives or 7 days, whichever is longer, before randomization

3.Patient is concurrently using other anti-cancer therapy.

4.Patient has a concurrent malignancy or malignancy within 3 years of randomization, with the exception of adequately treated, basal or squamous cell carcinoma, non-melanomatous skin cancer or curatively resected cervical cancer.

5. Patient has active cardiac disease or a history of cardiac dysfunction including any of the following:

•History of angina pectoris, symptomatic pericarditis, or myocardial infarction within 12 months prior to study entry

History of documented congestive heart failure (New York Heart Association functional classification III-IV)

Documented cardiomyopathy

•Patient has a Left Ventricular Ejection Fraction (LVEF) < 50% as determined by Multiple Gated acquisition (MUGA) scan or echocardiogram (ECHO)

◦History of any cardiac arrhythmias, e.g., ventricular, supraventricular, nodal arrhythmias, or conduction abnormality in the previous 12 months.
◦On screening, any of the following cardiac parameters:

bradycardia (heart rate < 50 at rest), tachycardia (heart rate > 90 at rest), PR interval > 220 msec, QRS interval >109 msec, or QTcF >450 msec.

•Systolic blood pressure >160 or <90 mmHg

REPUBLIC OF LEBANON Lebanon Clinical Trials Registry

6. Patient is currently receiving any of the following medications and cannot be discontinued 7 days prior start if the treatment:

•That are known strong inducers or inhibitors of CYP3A4.

•That have a known risk to prolong the QT interval or induce Torsades de Pointes.

•That have a narrow therapeutic window and are predominantly metabolized through CYP3A4.

Herbal preparations/medications

Type of study

Interventional Type of intervention Type of intervention: Specify type Pharmaceutical N/A Trial scope: Specify scope **Trial scope** N/A Therapy Study design: Allocation Study design: Masking Randomized controlled trial Blinded (masking used) Study design: Control Study phase Placebo 3 Study design: Purpose Study design: Specify purpose Treatment N/A Study design: Assignment Study design: Specify assignment Parallel N/A IMP has market authorization IMP has market authorization: Specify Yes, Lebanon and Worldwide Lebanon and Worldwide Name of IMP Year of authorization Month of authorization Ribociclib 2017 8 Type of IMP Others **Pharmaceutical class** Orally bioavailable, highly selective small molecule inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). Therapeutic indication postmenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer who received no prior therapy for advanced

Therapeutic benefit

increase OS & PFS

Study model

disease.

N/A

Study model: Specify model

N/A

Time perspective

Time perspective: Explain time perspective

Study model: Explain model

N/A

 \sim



Lebanon Clinical Trials Registry

Time perspective: Specify perspective	N/A
N/A	
Target follow-up duration	Target follow-up duration: Unit
Number of groups/cohorts	
Biospecimen retention	Biospecimen description
Samples with DNA**	Samples with circulating tumor DNA will be done, in addition to safety Labs (CBC, chemistry) sent to central lab : Covance located in Switzerland.
Target sample size	Actual enrollment target size
15	15
Date of first enrollment: Type	Date of first enrollment: Date
Actual	29/04/2014
Date of study closure: Type	Date of study closure: Date
Actual	20/12/2021
Recruitment status	Recruitment status: Specify
Complete	
Date of completion	
12/02/2015	
IPD sharing statement plan	IPD sharing statement description
Yes	Novartis is committed to sharing with qualified external
	researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
	This trial data is currently available according to the process described on www.clinicalstudydatarequest.com.
	URL: http://www.clinicalstudydatarequest.com
Additional data URL https://clinicaltrials.gov/ct2/show/record/NCT01958021?id=CLEE011A2301a	Rrank=1
Admin comments	
Trial data	
Trial status Approved	



Secondary Identifying Numbers		
Full name of issuing authority	Secondary identifying number	
Clinicaltrials.gov	NCT01958021	

Sources of Monetary or Material Support

Name

Novartis Pharma Services Inc.

Secondary Sponsors

No Sponsors

Contact for Public/Scientific Queries						
Contact type	Contact full name	Address	Country	Telephone	Email	Affiliation
Public	Joseph Kattan	Beirut	Lebanon	961363591 3	jkattan62@hotm ail.com	Hotel Dieu De France
Scientific	Hind Khairallah	Sin El Fil	Lebanon	+961 1 512002 Ext. 271	Hind.Khairallah@ fattal.com.lb	Khalil Fattal et Fils s.a.l.
Public	Fadi Farhat	Saida	Lebanon	03-753155	drfadi.trials@gm ail.com	Hammoud Hospital University Medical Center
Public	Fadi El Karak	Beirut	Lebanon	03-061621	felkarak@yahoo. com	Bellevue Medical Center
Public	Ziad Salem	Beirut	Lebanon	961134726 3	zs04@aub.edu.lb	American University of Beirut Medical Center




Centers/Hospitals Involved in the Study			
Center/Hospital name	Name of principles investigator	Principles investigator speciality	Ethical approval
Hotel Dieu De France	Dr Joseph Kattan	Hematology Oncology	Approved
Hammoud Hospital University Medical Center	Dr Fadi Farhat	Hematology Oncology	Approved
Bellevue Medical Center	Dr Fadi El Karak	Hematology Oncology	Approved
American University of Beirut Medical Center	Dr Ziad Salem	Hematology Oncology	Approved

Ethics Review				
Ethics approval obtained	Approval date	Contact name	Contact email	Contact phone
American University of Beirut Medical Center	05/09/2014	Fuad Ziyadeh	fz05@aub.edu.lb	+961 (0) 1 350 000 ext:5445
Hotel Dieu de France	20/09/2013	Sami Richa	cue@usj.edu.lb	961421229
Bellevue Medical Center	20/02/2014	Ghassan Maalouf	gmaalouf@bmc.com.lb	+961 (0) 1 682666 ext 5006
Hammoud Hospital University Medical Center	30/10/2013	Ahmad Zaatari	zaatari@hammoudhospital.com	+961 (0) 7 723111 ext 1160



Countries of Recruitment
Name
Lebanon
Argentina
Australia
Austria
Belgium
Brazil
Canada
Denmark
Finland
France
Germany
Hungary
Ireland
Italy
Netherlands
Norway
Singapore
Spain
Sweden
Turkey
United Kingdom
United States of America





Health Conditions or Problems Studied		
Condition Code Keyword		
Advanced Breast Cancer	Malignant neoplasm of breast (C50)	ABC

Interventions		
Intervention	Description	Keyword
Physical Exam, Vital signs, ECG, Echocardiography, Urinalysis, Serum/ urine pregnancy test, lab test, completion of QoL questionnaires	Physical Exam, Vital signs, ECG, Echocardiography, Urinalysis, Serum/ urine pregnancy test, lab test, completion of QoL questionnaires	ICF, Lab, IMP, radiology

Primary Outcomes		
Name	Time Points	Measure
Progression Free Survival	20 months	PFS up to approximately 20 months

Key Secondary Outcomes			
Name	Time Points	Measure	
•Overall Response Rate (ORR)	20 months	20 months	
Overall survival	65 months	65 months	





REPUBLIC OF LEBANON MINISTRY OF PUBLIC HEALTH Lebanon Clinical Trials Registry

Trial Results Summary results Study results globally Date of posting of results summaries Date of first journal publication of results **Results URL link Baseline characteristics** Participant flow Adverse events **Outcome measures** URL to protocol files